These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 25828118)

  • 1. Safety of dabigatran or rivaroxaban for thoracoscopic ablation in patients with atrial fibrillation.
    Im SI; Jeong DS; Park SJ; Park KM; Huh J; Kim JS; On YK
    Int J Cardiol; 2015; 186():213-5. PubMed ID: 25828118
    [No Abstract]   [Full Text] [Related]  

  • 2. Apixaban, Rivaroxaban, and Dabigatran in Patients Undergoing Atrial Fibrillation Ablation.
    Rillig A; Lin T; Plesman J; Heeger CH; Lemes C; Metzner A; Mathew S; Wissner E; Wohlmuth P; Ouyang F; Kuck KH; Tilz RR
    J Cardiovasc Electrophysiol; 2016 Feb; 27(2):147-53. PubMed ID: 26464027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left atrial thrombus and dense spontaneous echocardiographic contrast in patients on continuous direct oral anticoagulant therapy undergoing catheter ablation of atrial fibrillation: Comparison of dabigatran, rivaroxaban, and apixaban.
    Wu M; Gabriels J; Khan M; Shaban N; D'Amato S; Liu CF; Markowitz SM; Ip JE; Thomas G; Singh P; Lerman B; Patel A; Cheung JW
    Heart Rhythm; 2018 Apr; 15(4):496-502. PubMed ID: 29605015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.
    Phan K; Wang N; Pison L; Kumar N; Hitos K; Thomas SP
    Int J Cardiol; 2015 Apr; 185():209-13. PubMed ID: 25797679
    [No Abstract]   [Full Text] [Related]  

  • 5. [New Oral Anticoagulants During Catheter Ablation of Atrial Fibrillation. Experience With Rivaroxaban].
    Kazakov AI; Yashin SM; Lyan EV; Ayrapetyan AV
    Kardiologiia; 2015; 55(8):30-4. PubMed ID: 26761969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Postinterventional use of dabigatran in patients undergoing ablation therapy using an accelerated loading dose scheme - a single center experience.
    Seizer P; Gramlich M; Frische C; Gawaz M; Schreieck J
    Thromb Res; 2015 Aug; 136(2):486-7. PubMed ID: 26092430
    [No Abstract]   [Full Text] [Related]  

  • 7. Meta-analysis of efficacy and safety of rivaroxaban compared with warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation.
    Aryal MR; Ukaigwe A; Pandit A; Karmacharya P; Pradhan R; Mainali NR; Pathak R; Jalota L; Bhandari Y; Donato A
    Am J Cardiol; 2014 Aug; 114(4):577-82. PubMed ID: 24998087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of DOACs vs acenocoumarol in patients undergoing catheter ablation of atrial fibrillation.
    Vlachos K; Efremidis M; Bazoukis G; Letsas KP; Saplaouras A; Georgopoulos S; Karamichalakis N; Rokiza A; Sakellaropoulou A; Kolokathis AM; Efremidis T; Asvestas D; Sideris A
    Clin Cardiol; 2017 Oct; 40(10):847-852. PubMed ID: 28561951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Variations in Kidney Function on Nonvitamin K Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Recent Acute Heart Failure.
    Andreu-Cayuelas JM; Pastor-Pérez FJ; Puche CM; Mateo-Martínez A; García-Alberola A; Flores-Blanco PJ; Valdés M; Lip GY; Roldán V; Manzano-Fernández S
    Rev Esp Cardiol (Engl Ed); 2016 Feb; 69(2):134-40. PubMed ID: 26607030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome of non-vitamin K oral anticoagulants in the treatment of left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.
    Lin C; Quan J; Bao Y; Hua W; Ke M; Zhang N; Jin Q; Xie Y; Wei Y; Ling T; Pan W; Wu L; Xie Y
    J Cardiovasc Electrophysiol; 2020 Mar; 31(3):658-663. PubMed ID: 31975470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Nosebleed in new oral anticoagulant treatment - what should be done?].
    Stiefelhagen P
    MMW Fortschr Med; 2015 Sep; 157(15):25. PubMed ID: 26349711
    [No Abstract]   [Full Text] [Related]  

  • 12. Rivaroxaban and dabigatran in patients undergoing catheter ablation of atrial fibrillation.
    Providência R; Marijon E; Albenque JP; Combes S; Combes N; Jourda F; Hireche H; Morais J; Boveda S
    Europace; 2014 Aug; 16(8):1137-44. PubMed ID: 24550347
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uninterrupted direct oral anticoagulants vs. uninterrupted vitamin K antagonists during catheter ablation of non-valvular atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials.
    Romero J; Cerrud-Rodriguez RC; Diaz JC; Michaud GF; Taveras J; Alviz I; Grupposo V; Cerna L; Avendano R; Kumar S; Kirchhof P; Natale A; Di Biase L
    Europace; 2018 Oct; 20(10):1612-1620. PubMed ID: 29982383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network meta-analysis of efficacy and safety of competitive oral anticoagulants in patients undergoing radiofrequency catheter ablation of atrial fibrillation.
    Li PJ; Xiao J; Yang Q; Feng Y; Wang T; Liu GJ; Liang ZA
    J Interv Card Electrophysiol; 2016 Sep; 46(3):213-24. PubMed ID: 27001171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periprocedural Management of New Oral Anticoagulants in Atrial Fibrillation Ablation.
    Zak M; Castiblanco SA; Garg J; Palaniswamy C; Jacobs LE
    J Cardiovasc Pharmacol Ther; 2015 Sep; 20(5):457-64. PubMed ID: 25827857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prescribing of Direct Oral Anticoagulants in Atrial Fibrillation Based on Estimation of Renal Function Using Standard and Modified Cockcroft-Gault Equations: A Retrospective Analysis.
    Kucey M; Bolt J; Albers L; Bell A; Iroh N; Toppings J
    Can J Hosp Pharm; 2016; 69(5):409-414. PubMed ID: 27826159
    [No Abstract]   [Full Text] [Related]  

  • 17. Early non-persistence with dabigatran and rivaroxaban in patients with atrial fibrillation.
    Jackevicius CA; Tsadok MA; Essebag V; Atzema C; Eisenberg MJ; Tu JV; Lu L; Rahme E; Ho PM; Turakhia M; Humphries KH; Behlouli H; Zhou L; Pilote L
    Heart; 2017 Sep; 103(17):1331-1338. PubMed ID: 28286333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety of early initiation of rivaroxaban or dabigatran after thrombolysis in acute ischemic stroke.
    Ritzenthaler T; Derex L; Davenas C; Bnouhanna W; Farghali A; Mechtouff L; Cho TH; Nighoghossian N
    Rev Neurol (Paris); 2015 Sep; 171(8-9):613-5. PubMed ID: 25857461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful direct thrombin inhibitor treatment of a left atrial appendage thrombus developed under rivaroxaban therapy].
    Szegedi N; Gellér L; Tahin T; Merkely B; Széplaki G
    Orv Hetil; 2016 Jan; 157(4):154-6. PubMed ID: 26772828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of short-term use of dabigatran or rivaroxaban for direct-current cardioversion in patients with atrial fibrillation and atrial flutter.
    Yadlapati A; Groh C; Passman R
    Am J Cardiol; 2014 Apr; 113(8):1362-3. PubMed ID: 24576547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.